Ann: CSIRO to assist Rhythm Biosciences develop key reagents, page-8

"Is RHY too late to the party?"

I don't think so. The clinical trials required to prove that 8 different cancers can be detected and identified in their early stages will be hellishly complex. It's really ambitious, although I hope of course for all our sakes they have success. And then there's the cost, they are estimating $500 per test.

Meanwhile RHY are targetting bowel cancer in isolation. My feeling is they can get a cheaper and better product to market faster than this lot, especially with the progress thay have already made and with the backing of the CSIRO.

Anyway, I hope I am right!